Activity-Dependent Antioxidant Gene Therapy Shows Promise in Suppressing Epileptogenesis
核心洞察
A cfos-driven Nrf2 (搜索) gene therapy delivered via AAV9 (搜索) significantly reduced seizure frequency in a mouse model of epilepsy (搜索) over 12 weeks of monitoring.
The therapy leverages neuronal activity-dependent expression, ensuring antioxidant gene activation occurs selectively in response to seizure activity.
Weekly seizure frequency was markedly lower in cfos-Nrf2 (搜索) treated animals compared to cfos-EGFP controls, demonstrating anti-epileptogenic efficacy.
A novel gene therapy approach that harnesses activity-dependent antioxidant responses has demonstrated significant potential in suppressing the development of epilepsy (搜索), according to new preclinical research. The study, which employed an adeno-associated virus serotype 9 (AAV9 (搜索)) vector to deliver a cfos-driven Nrf2 (搜索) construct, showed durable reductions in seizure frequency in a mouse model, offering a potential disease-modifying strategy for a condition that remains refractory to conventional antiseizure medications in approximately one-third of patients.
The findings address a critical unmet need in epilepsy (搜索) treatment. As noted in the broader scientific literature, drug resistance affects a substantial proportion of individuals with epilepsy, and current pharmacotherapies primarily provide symptomatic control without altering the underlying disease process. The concept of epileptogenesis—the process by which a normal brain becomes prone to seizures—has emerged as a key target for intervention, yet no approved therapies exist to prevent or reverse this progression.
Activity-Dependent Expression Strategy
The gene therapy platform relies on a cfos promoter to drive transgene expression selectively in neurons that are actively firing. Validation experiments confirmed that cfos-driven EGFP expression colocalized with NeuN-positive neurons and was absent in GFAP-positive astrocytes, confirming neuronal specificity. Quantification of mean fluorescence intensity for EGFP per NeuN-positive cell in CA1 and CA3 hippocampal subfields demonstrated time-dependent induction of the cfos-driven construct following status epilepticus (SE), with measurements taken at sham and 4–48 hours post-SE (n = 3 animals per group).
This activity-dependent mechanism is central to the therapeutic rationale: by linking antioxidant gene expression to neuronal activity, the intervention is designed to deliver protective effects precisely when and where they are needed—during and following seizure events.
Anti-Epileptogenic Efficacy
In a sequential pentylenetetrazol (PTZ) paradigm, animals expressing cfos-Nrf2 (搜索) were compared with cfos-EGFP controls. Racine seizure scores were assessed following PTZ injections at 0 hours, 24 hours, and 2 weeks (n = 12 animals, with 4 excluded per predefined criteria). The treatment group showed attenuated seizure responses.
Long-term anti-epileptogenic efficacy was evaluated through 12 weeks of video-electrocorticography (vECoG) monitoring. Weekly seizure frequency in cfos-Nrf2 (搜索) animals was significantly lower than in cfos-EGFP controls (n = 7 animals per group). Immunofluorescence at 13 weeks post-SE confirmed persistent cfos-driven expression in response to spontaneous seizures, indicating that the therapeutic construct remained responsive to endogenous seizure activity throughout the monitoring period.
Effects in Chronic Epilepsy (搜索)
The study also examined the gene therapy's impact in animals with established chronic epilepsy (搜索). Cumulative normalized seizure burden was tracked over 12 weeks, with AAV9 (搜索) injection administered at the time point indicated during the monitoring period. At week 12, total seizure counts were significantly reduced in cfos-Nrf2 (搜索) animals compared to cfos-EGFP controls (n = 7 animals per group).
Statistical analyses employed one-way ANOVA with Tukey post hoc test, Mann-Whitney test, and two-way ANOVA mixed-effects with Sidak post hoc test as appropriate, with significance thresholds set at p<0.05.
Implications for Gene Therapy in Neurology
The results contribute to a growing body of evidence supporting gene therapy approaches for neurological disorders. AAV vectors have gained prominence for central nervous system applications due to their ability to transduce neurons and sustain long-term transgene expression. The cfos-Nrf2 (搜索) strategy adds a layer of biological sophistication by coupling therapeutic gene expression to the pathological activity it aims to counteract, potentially minimizing off-target effects and optimizing the timing of antioxidant delivery.
While the findings are preclinical, they highlight a conceptual advance in epilepsy (搜索) therapy: moving beyond symptomatic seizure suppression toward interventions that may modify the disease trajectory. Further research will be needed to evaluate translational potential, including safety profiles, dosing parameters, and efficacy in additional models.